A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 3, 1997, Pages 141-153

  Smilde, Johan G ^a  

^a Refaja Ziekenhuis Stadskanaal   (Netherlands)

Author keywords

adverse events; ambulatory blood pressure; amlodipine; compliance; felodipine extended release; therapeutic coverage

Indexed keywords

AMLODIPINE; FELODIPINE;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE;

EID: 0030971168     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80009-4     Document Type: Article

References (25)

1. Opie LH. Clinical Use of Calcium Antagonist Drugs, 2nd ed. Boston: Kluwer Academic Publisher; 1990.
2. Nayler WG. Second Generation of Calcium Antagonists. Berlin: Springer-Verlag; 1991.
3. Nayler WG. Amlodipine. Berlin: Springer-Verlag; 1993.
4. Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995;50:560-586.
5. Abernathy DR. The pharmacokinetic profile of amlodipine. Am Heart J. 1989;118:1100-1103.
6. Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992;44:251-277.
7. Bainbridge AD, Herlihy O, Meredity PA, Elliott HL. A comparative assessment of amlodipine and felodipine ER: Pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol. 1993;45:425-430.
8. Rudd P, Ahmed S, Zachary V, et al. Issues in patient compliance: The search for therapeutic sufficiency. Cardiology. 1992;80(Suppl 1):2-10.
9. CPMP Working Party on Efficacy of Medicinal Products. EEC note for guidance: Good clinical practice for trials on medicinal products in the European community. Pharmacol Toxicol. 1990;67:361-372.
10. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society Protocol. J Hypertens. 1991;9:573-574.
11. O'Brien E, O'Malley K, Mee F, et al. Ambulatory blood pressure measurement in the diagnosis and management of hypertension. J Human Hypertens. 1991;5:23-30.
12. Mulcahy D, Purcell H, Sparrow J, et al. Effects of amlodipine versus diltiazem on morning peak in myocardial ischemic activity in angina pectoris. Am J Cardiol. 1993;72:1203-1206.
13. Palatini P. Clinical significance of the diurnal blood pressure rhythm and of blood pressure variability evaluated with non invasive ambulatory monitoring. High Blood Press. 1993;2(Suppl 1):88-89.
14. Meredith PA, Perloff D, Mancia G, Pickering T. Blood pressure variability and its implications for antihypertensive therapy. Blood Pressure. 1995;4:5-11.
15. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther. 1994;16:316-326.
16. Ramsay JA. Participants in noncompliance research: Compliant or non-compliant? Med Care. 1982;20:615-622.
17. Keen PJ. What is the best dosage schedule for patients? J Royal Soc Med. 1991;84:640-641. Editorial.
18. Hernandez-Hernandez R, Armas-Hernandez MJ, Armas-Padilla MC, et al. Amlodipine and enalapril. Comparative effect on circadian rhythm during therapy and after missing a dose. Am J Hypertens. 1995;8:75A. Abstract.
19. Mancia G, Omboni S. Antihypertensive efficacy of amlodipine vs fosinopril as assessed by 48 hour ambulatory blood pressure monitoring in isolated systolic hypertension. J Hypertens. 1995;13:115. Poster.
20. Leenen FH, Fourney A, Notman G, Janner J. Persistence of anti-hypertensive effect after "missed doses" of calcium-antagonist with long (amlodipine) vs short (diltiazem) elimination half life. Br J Clin Pharmacol. 1996;41:83-88.
21. Trazzi S, Mutti E, Frattola A, et al. Reproducibility of non-invasive and intra-arterial blood pressure monitoring: Implications for studies on hypertensive treatment. J Hypertens. 1991;9:115-119.
22. Mansoor GA, McCabe EJ, White WB. Long-term reproducibility of ambulatory blood pressure. J Hypertens. 1994;12:703-708.
23. Conway J, Johnston J, Coats A, et al. The use of ambulatory blood pressure monitoring to improve the accuracy and to reduce the number of subjects in clinical trials of hypertensive agents. J Hypertens. 1988;6:111-116.
24. Coats AS, Radaelli A, Clark SJ, et al. The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertens. 1992;10: 385-391.
25. Staessen JA, Thijs L, Mancia G, et al. Clinical trials with ambulatory blood pressure monitoring: Fewer patients needed? Lancet. 1994;344:1552-1556.